Zimmermann Michael B, Jooste Pieter L, Mabapa Ngoako Solomon, Schoeman Serena, Biebinger Ralf, Mushaphi Linda F, Mbhenyane Xikombiso
Laboratory for Human Nutrition, Swiss Federal Institute of Technology, Zürich, Switzerland.
Am J Clin Nutr. 2007 Oct;86(4):1040-4. doi: 10.1093/ajcn/86.4.1040.
Vitamin A (VA) deficiency (VAD) and iodine deficiency (ID) often coexist in children in Africa. VAD may affect thyroid function and the response to iodine prophylaxis.
The aim was to investigate the effects of supplementation with iodine or VA alone, and in combination, in children with concurrent VAD and ID.
A 6-mo randomized, double-blind, 2 x 2 intervention trial was conducted in 5-14 y-old South African children (n = 404), who, on average, had mild-to-moderate VAD and ID. At baseline and after 3 mo, children received 1) iodine (191 mg I as oral iodized oil) + placebo (IS group), 2) VA (200000 IU VA as retinyl palmitate) + placebo (VAS group), 3) both iodine and VA (IS+VAS group), or 4) placebo. At baseline, 3 mo, and 6 mo, urinary iodine (UI), thyroid volume, thyrotropin (thyroid-stimulating hormone; TSH), total thyroxine (TT(4)), thyroglobulin, serum retinol (SR), and retinol-binding protein (RBP) were measured.
SR and RBP increased significantly with VA supplementation (P < 0.05). For UI, SR, and RBP, there were no significant treatment interactions between iodine and vitamin A. The 3-factor and all three 2-factor interactions were significant for thyroid volume, TSH, and thyroglobulin (P < 0.001), whereas none of these interactions were significant for TT(4). There was a clear effect of VAS without IS on TSH, thyroglobulin, and thyroid volume; all 3 variables decreased significantly (P < 0.05).
Iodine prophylaxis is effective in controlling ID in areas of poor vitamin A status. VA supplements are effective in treating VAD in areas of mild ID and have an additional benefit-through suppression of the pituitary TSHbeta gene, VAS can decrease excess TSH stimulation of the thyroid and thereby reduce the risk of goiter and its sequelae.
在非洲儿童中,维生素A(VA)缺乏(VAD)和碘缺乏(ID)常常并存。VAD可能会影响甲状腺功能以及对碘预防措施的反应。
旨在研究单独补充碘或VA以及联合补充碘和VA对同时患有VAD和ID的儿童的影响。
对404名5至14岁的南非儿童进行了一项为期6个月的随机、双盲、2×2干预试验,这些儿童平均患有轻度至中度的VAD和ID。在基线期和3个月后,儿童接受以下处理:1)碘(191毫克碘,以口服碘油形式)+安慰剂(IS组),2)VA(200000国际单位VA,以棕榈酸视黄酯形式)+安慰剂(VAS组),3)碘和VA两者(IS+VAS组),或4)安慰剂。在基线期、3个月和6个月时,测量尿碘(UI)、甲状腺体积、促甲状腺素(甲状腺刺激激素;TSH)、总甲状腺素(TT4)、甲状腺球蛋白、血清视黄醇(SR)和视黄醇结合蛋白(RBP)。
补充VA后,SR和RBP显著增加(P<0.05)。对于UI、SR和RBP,碘和维生素A之间没有显著的治疗交互作用。甲状腺体积、TSH和甲状腺球蛋白的三因素以及所有三个二因素交互作用均显著(P<0.001),而这些交互作用对TT4均无显著影响。在没有IS的情况下,VAS对TSH、甲状腺球蛋白和甲状腺体积有明显影响;所有这3个变量均显著降低(P<0.05)。
在维生素A状况较差的地区,碘预防措施在控制ID方面有效。VA补充剂在轻度ID地区治疗VAD有效,并且还有额外益处——通过抑制垂体TSHβ基因,VAS可以减少TSH对甲状腺的过度刺激,从而降低甲状腺肿及其后遗症的风险。